These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 34064299)

  • 1. Development and Validation of Enzyme-Linked Immunosorbent Assay for Group B Streptococcal Polysaccharide Vaccine.
    Jang AY; Choi MJ; Zhi Y; Ji HJ; Noh JY; Yoon JG; Cheong HJ; Kim WJ; Seo HS; Song JY
    Vaccines (Basel); 2021 May; 9(6):. PubMed ID: 34064299
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of a multiplexed opsonophagocytic killing assay (MOPA) for group B Streptococcus.
    Choi MJ; Noh JY; Cheong HJ; Kim WJ; Lin SM; Zhi Y; Lim JH; Lim S; Seo HS; Song JY
    Hum Vaccin Immunother; 2018 Jan; 14(1):67-73. PubMed ID: 28933634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type III group B streptococcal polysaccharide induces antibodies that cross-react with Streptococcus pneumoniae type 14.
    Guttormsen HK; Baker CJ; Nahm MH; Paoletti LC; Zughaier SM; Edwards MS; Kasper DL
    Infect Immun; 2002 Apr; 70(4):1724-38. PubMed ID: 11895934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural acquired humoral immunity against serotype-specific group B Streptococcus rectovaginal colonization acquisition in pregnant women.
    Kwatra G; Adrian PV; Shiri T; Buchmann EJ; Cutland CL; Madhi SA
    Clin Microbiol Infect; 2015 Jun; 21(6):568.e13-21. PubMed ID: 25680313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Protective Value of Maternal Group B Streptococcus Antibodies: Quantitative and Functional Analysis of Naturally Acquired Responses to Capsular Polysaccharides and Pilus Proteins in European Maternal Sera.
    Fabbrini M; Rigat F; Rinaudo CD; Passalaqua I; Khacheh S; Creti R; Baldassarri L; Carboni F; Anderloni G; Rosini R; Maione D; Grandi G; Telford JL; Margarit I
    Clin Infect Dis; 2016 Sep; 63(6):746-753. PubMed ID: 27402816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of group B streptococcus type III polysaccharide-specific antibody concentrations in human sera is antigen dependent.
    Bhushan R; Anthony BF; Frasch CE
    Infect Immun; 1998 Dec; 66(12):5848-53. PubMed ID: 9826364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of a 6-plex Luminex-based assay for measuring human serum antibodies to group B streptococcus capsular polysaccharides.
    Gaylord MA; Larrier M; Giordano-Schmidt D; Grube CD; Singh S; Nguyen HH; McKeen A; Tan CY; Anderson AS; Kalina WV; Pavliakova D; Giardina PC
    Hum Vaccin Immunother; 2024 Dec; 20(1):2311480. PubMed ID: 38608171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opsonophagocytic Antibodies to Serotype Ia, Ib, and III Group B Streptococcus among Korean Infants and in Intravenous Immunoglobulin Products.
    Kim HW; Lee JH; Cho HK; Lee H; Seo HS; Lee S; Kim KH
    J Korean Med Sci; 2017 May; 32(5):737-743. PubMed ID: 28378545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Multiplex Immunoassays for Quantification of IgG against Group B
    Buffi G; Galletti B; Stella M; Proietti D; Balducci E; Romano MR; Mori E; Fabbrini M; Giuliani MM; Berti F; Margarit I
    mSphere; 2019 Aug; 4(4):. PubMed ID: 31391276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-stratified analysis of serotype-specific baseline immunity against group B streptococcus.
    Choi MJ; Noh JY; Jang AY; Cheong HJ; Kim WJ; Song DJ; Cho GJ; Oh MJ; Zhi Y; Seo HS; Song JY
    Hum Vaccin Immunother; 2020 Jun; 16(6):1338-1344. PubMed ID: 31687869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroprevalence of Opsonophagocytic Antibodies against Serotype Ia, Ib, II, III, and V Group B Streptococcus among Korean Population.
    Lee JH; Kim HW; Kim KH
    J Korean Med Sci; 2018 Apr; 33(16):e127. PubMed ID: 29651820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III.
    Baker CJ; Rench MA; Fernandez M; Paoletti LC; Kasper DL; Edwards MS
    J Infect Dis; 2003 Jul; 188(1):66-73. PubMed ID: 12825173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.
    Madhi SA; Cutland CL; Jose L; Koen A; Govender N; Wittke F; Olugbosi M; Meulen AS; Baker S; Dull PM; Narasimhan V; Slobod K
    Lancet Infect Dis; 2016 Aug; 16(8):923-34. PubMed ID: 27139805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of cross-reactive antibodies by immunization of healthy adults with types Ia and Ib group B streptococcal polysaccharide-tetanus toxoid conjugate vaccines.
    Brigtsen AK; Kasper DL; Baker CJ; Jennings HJ; Guttormsen HK
    J Infect Dis; 2002 May; 185(9):1277-84. PubMed ID: 12001045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine.
    Paoletti LC; Wessels MR; Rodewald AK; Shroff AA; Jennings HJ; Kasper DL
    Infect Immun; 1994 Aug; 62(8):3236-43. PubMed ID: 8039893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a tetravalent group B streptococcal polysaccharide vaccine in healthy adults.
    Kotloff KL; Fattom A; Basham L; Hawwari A; Harkonen S; Edelman R
    Vaccine; 1996 Apr; 14(5):446-50. PubMed ID: 8735558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review of Group B Streptococcal capsular types, sequence types and surface proteins as potential vaccine candidates.
    Bianchi-Jassir F; Paul P; To KN; Carreras-Abad C; Seale AC; Jauneikaite E; Madhi SA; Russell NJ; Hall J; Madrid L; Bassat Q; Kwatra G; Le Doare K; Lawn JE
    Vaccine; 2020 Oct; 38(43):6682-6694. PubMed ID: 32888741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population-based active surveillance for neonatal group B streptococcal infections in Alberta, Canada: implications for vaccine formulation.
    Davies HD; Raj S; Adair C; Robinson J; McGeer A;
    Pediatr Infect Dis J; 2001 Sep; 20(9):879-84. PubMed ID: 11734768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III.
    Hillier SL; Ferrieri P; Edwards MS; Ewell M; Ferris D; Fine P; Carey V; Meyn L; Hoagland D; Kasper DL; Paoletti LC; Hill H; Baker CJ
    Clin Infect Dis; 2019 May; 68(12):2079-2086. PubMed ID: 30281066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review of the clinical development of group B streptococcus serotype-specific capsular polysaccharide-based vaccines.
    Dzanibe S; Madhi SA
    Expert Rev Vaccines; 2018 Jul; 17(7):635-651. PubMed ID: 29961350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.